two-step radioimmunotherapy (Y-mAbs Therapeutics)

N/A

Report date: 2025/09/24 16:01:13
NME

Base Information

Drug Nametwo-step radioimmunotherapy (Y-mAbs Therapeutics)
Drug Alias NameGD2-SADA:177Lu-DOTA complexGD2-SADA and 177Lu-DOTA
ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Radionuclide Drug Conjugates
Mechanisms of ActionIonising radiation emittersDisialoganglioside GD2 modulators
TargetsDisialoganglioside GD2
Therapy Area/IndicationsSolid tumoursSmall Cell Lung CarcinomaMelanoma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMassachusetts Institute Of TechnologyMemorial Sloan Kettering Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesY-Mabs Therapeutics IncMemorial Sloan Kettering Cancer CenterMassachusetts Institute Of Technology
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaMelanoma +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A